Required to complete NBS for lysosomal disorders and second-tier testing for XALD, CAH, and LD NBS disorders.

Fisher Scientific Company LLC was awarded a Texas state contract (ID: HHSTX-6-0000381888) focused on newborn screening (NBS) testing for specific lysosomal disorders. The contract requires the completion of primary screening and second-tier testing for X-linked adrenoleukodystrophy (XALD), Congenital Adrenal Hyperplasia (CAH), and additional lysosomal disorders (LD).

The contract, awarded on August 11, 2025, involves laboratory testing services utilizing specialized chemical reagents, as indicated by the NIGP code 17513 for laboratory chemicals. While specific contract value details are not provided, the award appears to be for critical medical diagnostic services. The contract's UNSPSC codes suggest potential involvement with rare earth metals and elemental compounds, which may be relevant to the diagnostic testing methodologies, though the direct connection is not explicitly detailed in the available documentation.